



BRAWN



9B7A1

CIN NO.: L74899DL1985PLC022468

To,
The Secretary,
Listing Department,
BSE Limited,
Floor 25, Phirozee Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Date: 12-02-2022

SCRIP CODE: 530207

SUB: UNAUDITED FINANCIAL RESULTS FOR THE 3RD QUARTER ENDED 31ST DECEMBER 2021, AS PER REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Dear Sir,

We wish to inform you that pursuant to Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company, at its meeting held on today February 12, 2022 inter-alia considered and approved/noted the following:

1. Standalone Un-audited Financial Results for the quarter ended 31st December, 2021
2. Limited Review Report on the unaudited financial results for the quarter ended 31st December, 2021.

The extract of above said results also being published in the newspapers, in the prescribed format.

The meeting of the Board of Directors commenced at 03:00 P.M. and concluded at 04:00 P.M.

Please acknowledge the receipt of the Letter and take the same on record.

You are requested to take above on record.

Thanking you,

For BRAWN BIOTECH LIMITED


Priyanka Sharma
Company Secretary & Compliance Officer
Encl: As above




BRAWN BIOTECH LTD.

(Formerly Known as Brawn Pharmaceuticals Ltd.)

...for better life

Regd. Office : C-64, Lajpat Nagar-1, New Delhi-110024, INDIA Tel: 01129815331
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Corporate Office : Plot No. - 30, Sector - 33, Near Hero Honda Factory, Gurugram - 122001, Haryana, INDIA Tel: 0124-4666152, 4222462
Email: solution@brawnbiotech.com, Web site : www.brawnbiotech.com



BRAWN



9210D

CIN NO.: L74899DL1985PLC022468

BRAWN BIOTECH LIMITED						
CIN:L74899DL1985PLC022468						
REGD. OFFICE: C-64, Lajpat Nagar-1, New Delhi 110024						
STATEMENT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER 2021						
Sr.	Particulars	Quarter ended			Nine Months ended	
		31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020
		Un-audited	Un-audited	Un-audited	Un-audited	Un-audited
						Year Ended 31.03.2021 Audited
1	Revenue from operations					
	Revenue from operations	252.78	207.77	1,478.22	573.34	3,191.40
	Other Income	-	9.05	0.03	9.19	0.08
	Total Revenue	252.78	216.82	1,478.26	582.54	3,191.48
2	Expenses					
a	Cost of material consumed	-	-	-	-	164.43
b	Purchase of stock-in-trade	422.47	264.22	1,488.68	726.85	3,050.30
c	Change in inventories of finished goods, work in progress and stock in trade	-133.87	-101.81	-139.26	-238.35	-148.66
d	Employee Benefit expenses	31.91	49.48	61.15	135.41	166.45
e	Depreciation and amortisation expenses	1.50	0.93	0.80	3.33	2.58
f	Finance Cost	0.15	5.33	0.23	5.73	1.72
g	Other expenses	87.35	47.58	48.42	177.00	113.93
	Total Expenses	409.51	265.73	1,460.01	809.98	3,186.31
	Profit from Operation before Other Income, exceptional and extra-ordinary Items					
3	(1-2)	-156.73	-48.91	18.24	-227.44	5.17
4	Other income	-	-	-	-	-
5	Profit from ordinary activities before exceptional items (3-4)	-156.73	-48.91	18.24	-227.44	5.17
6	Exceptional Items	-	-	-	-	-
7	Profit from ordinary activities before tax (5-6)	-156.73	-48.91	18.24	-227.44	5.17
8	Tax Expenses	-	-	-	-	19.07
9	Profit (loss) for the period from continuing operations (7-8)	-156.73	-48.91	18.24	-227.44	5.17
10	Profit/(loss) from discontinuing operations	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-	-
13	Profit (loss) for the period (9+12)	-156.73	-48.91	18.24	-227.44	5.17
14	Other Comprehensive Income	-2.08	7.85	-0.09	5.21	-6.67
	Total Comprehensive Income	-158.81	-41.06	18.15	-222.23	-1.50
15	Details of equity share capital	300.03	300.03	300.03	300.03	300.03
	Paid-up equity share capital	-	-	-	-	-
	Face value of equity share capital	-	-	-	-	-
16	Reserve excluding Revaluation Reserve	-	-	-	-	-
17	Earnings per share					
i	Basic earnings per share	-5.29	-1.37	0.60	-7.41	-0.05
ii	Diluted earnings per share	-5.29	-1.37	0.60	-7.41	-0.05

NOTES :-

1 Results for the quarter ended on 31st December, 2021 were reviewed by the Audit committee and then approve by the Board of Directors at their meeting held on 12 February, 2022.

The Statutory Auditors carried out the limited review for quarter ended 31st December, 2021. The management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.

The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment rules), 2016 prescribed under Section 133 of the companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

4 The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.

5 The above Standalone Un-audited Financial Results for the quarter ended on 31-12-2021 are available on company's website www.brawnbiotech.com and BSE website www.bseindia.com.

6 Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board
For Brawn Biotech Limited

Brij Raj Gupta
Director
CIN NO. 00974969
Date : 12.02.2022
Place: Delhi

BRAWN BIOTECH LTD.

(Formerly Known as Brawn Pharmaceuticals Ltd.)

Regd. Office : C-64, Lajpat Nagar-1, New Delhi-110024, INDIA Tel: 01129815331
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Corporate Office : Plot No. - 30, Sector - 33, Near Hero Honda Factory, Gurugram - 122001, Haryana , INDIA Tel: 0124-4666152, 4222462
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

...for better life



RAJIV UDAI & ASSOCIATES
CHARTERED ACCOUNTANTS

To,
The Board of Directors of
Brawn Biotech Limited

We have reviewed the accompanying statement of unaudited financial results of **Brawn Biotech Limited** for the period ended 31st December 2021. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of this matter.

For Rajiv Udai & Associates
Chartered Accountants
Firm Registration No. 018764N


Rajeev Jam

Partner

Membership No. 099767

UDIN: 22099767ABNDFP7734



Place: Delhi

Date: 12-02-2022